The Novo Nordisk Foundation is partnering with the Broad Institute of MIT and Harvard University to launch a massive genetic data mining project that aims to gain deeper insight into how human genetic variants affect risk for common complex diseases.

Biotech and pharmaceutical companies and health care institutions are on the front lines of not only fighting COVID-19, but working to develop vaccines and therapies against the respiratory illness – often in unexpected ways.

Biogen Inc. joined a consortium to build a collection of biological and medical data, where the company’s employees who had tested for and recovered from the coronavirus would be able to participate.

Scientists at the Broad Institute of MIT and Harvard tested about 4,518 drugs on 578 human cancer cell lines, and discovered that almost 50 had previously unrecognized anti-cancer properties.